Explore how the Consolidated Appropriations Act (CAA) 2026 and proposed PBM Kickback Prohibition Act are increasing expectations for transparency, documentation, and performance monitoring in pharmacy benefits.
In this video, Truveris Clinical Director Aya Desouki, PharmD, explains how the CAA 2026 and proposed PBM Kickback Prohibition Act are reshaping pharmacy benefit oversight, fiduciary responsibilities, and transparency expectations for plan sponsors.
Video Highlights
- How CAA 2026 reforms are expanding PBM reporting, disclosure, and transparency requirements for plan sponsors
- What new pass-through provisions may mean for rebates, fees, discounts, and other manufacturer-related value
- Why the proposed PBM Kickback Prohibition Act is bringing more attention to PBM procurement and compensation practices
- How these developments may shift pharmacy benefit oversight from a vendor management function to a more active governance responsibility
